IL6 and rheumatoid arthritis: Several biologic disease modifying anti-rheumatic drugs (bDMARDs) introduced in recent years target pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6), which are elevated in patients with inflammatory conditions such as RA [6, 7].